Jean Sung

Dr. Sung has spent over a decade developing novel particle engineering and formulation technologies to advance respiratory dry powder drug delivery.

Dr. Sung joined Pulmatrix in 2008, leading the formulation, process, particle engineering and analytical chemistry development functions.

Prior to her graduate studies, Dr. Sung was an early employee at Advanced Inhalation Research (AIR®) Inc. and later Alkermes, Inc. after the acquisition of AIR, where she advanced formulation development of the pulmonary drug delivery platform technology across small molecule and macromolecule therapies.

Dr. Sung has numerous scientific publications and patents/applications in drug delivery, primarily focused on particle formulations for inhaled therapeutics.

Dr. Sung has a S.B. in Chemical Engineering from Massachusetts Institute of Technology and holds a Ph.D. and M.S. in Engineering Sciences with a focus on Biomedical Engineering from Harvard University.

Jean Sung is the Vice President of Pharmaceutical Development at Pulmatrix. With a background in Biotechnology, Jean Sung has a rich history of leadership and innovation.Jean Sung studied MS Biomedical Engineering at Harvard University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.